Metabolic Enhancement of Ferroptosis and Cuproptosis in Tumor Therapy

Study Background and Research Question

Regulated cell death (RCD) is fundamental to cancer therapy development, with ferroptosis and cuproptosis emerging as promising modalities targeting metabolic vulnerabilities in malignant cells. Ferroptosis, driven by iron-dependent lipid peroxidation, and cuproptosis, a copper-induced mitochondrial death pathway, both disrupt tumor homeostasis but are governed by distinct and partially overlapping metabolic processes. Despite the proven role of metal-based nanomaterials in activating these pathways, strategies for their simultaneous sensitization have remained underexplored. The reference study by Zhang et al. addresses whether metabolic reprogramming—specifically via glycolysis and NAD+ metabolism inhibition—can enhance both ferroptosis and cuproptosis in tumors, thereby boosting anti-tumor immunity (paper).

Key Innovation from the Reference Study

The central innovation of Zhang et al. lies in the design of a composite nanosystem (SCu/L) that co-delivers a glycolysis/NAD+ metabolism inhibitor (STF-31) and copper within a lipid bilayer, forming a copper-tannic acid (Cu-TA) network. This metabolic intervention serves a dual purpose: it disrupts cellular energy metabolism and redox homeostasis while simultaneously increasing mitochondrial copper accumulation and suppressing copper efflux. This dual targeting approach is shown to synergistically sensitize tumor cells to both cuproptosis and ferroptosis, leading to enhanced immunogenic cell death and remodeling of the tumor immune microenvironment (paper).

Methods and Experimental Design Insights

The authors synthesized the SCu/L nanosystem by encapsulating STF-31 within a Cu-TA/liposome hybrid structure. Detailed physicochemical characterization confirmed nanoscale integrity and efficient drug loading. Cellular uptake studies utilized fluorescent labeling to track intracellular distribution, with particular attention to mitochondrial copper delivery. Functional assays measured glycolytic flux, NAD+ levels, ATP content, and Cu-ATPase activity, providing mechanistic evidence for metabolic disruption. Key cell death readouts included lipid peroxidation (for ferroptosis), protein aggregation (for cuproptosis), and markers of immunogenic cell death. In vivo, the antitumor efficacy and immune activation were evaluated in murine tumor models, with immune cell profiling performed on tumor-infiltrating lymphocytes (paper).

Core Findings and Why They Matter

The SCu/L nanosystem achieved several mechanistically significant outcomes:

• Metabolic Disruption: SCu/L substantially decreased intracellular glucose, NAD+, NADPH, and ATP, directly impairing both glycolysis and compensatory NAD+ salvage pathways. This metabolic stress impaired GSH synthesis, a key regulator of cellular redox status, and suppressed Cu-ATPase activity, reducing copper efflux (paper).
• Enhanced Ferroptosis and Cuproptosis: Tumor cells treated with SCu/L exhibited increased mitochondrial copper accumulation and iron-sulfur cluster protein destabilization, resulting in simultaneous induction of ferroptosis (evidenced by lipid peroxidation) and cuproptosis (by mitochondrial protein oligomerization) (paper).
• Immunogenic Cell Death and Tumor Immunity: The metabolic intervention not only increased tumor cell death but also promoted a robust immunogenic response, as demonstrated by elevated dendritic cell activation and T cell infiltration in tumor tissues (paper).

Collectively, these results suggest that targeting tumor metabolic flexibility can substantially enhance the therapeutic index of metal-based cancer nanotherapies—an insight with direct translational implications for regulated cell death modulation and immunotherapy.

Comparison with Existing Internal Articles

Several internal resources provide context for the use of metabolic intervention strategies and iron chelation in cancer research. For example, "DeferoxamineB: Strategic Iron Chelation for Translational Oncology" discusses how Deferoxamine (DeferoxamineB) enables precise manipulation of iron metabolism and oxidative stress in cancer models, supporting approaches similar to those in the reference study. Another relevant piece, "Deferoxamine (DeferoxamineB): Iron Chelator & Cancer Research Tool", highlights the compound’s antiproliferative and apoptosis-inducing effects, which align conceptually with ferroptosis and cuproptosis induction. However, the current reference paper uniquely integrates copper metabolism and glycolytic inhibition within a nanoplatform to achieve dual RCD sensitization and immune modulation—a step beyond single-agent iron chelation or apoptosis induction.

Limitations and Transferability

While the SCu/L nanosystem demonstrates clear efficacy in preclinical models, several limitations remain. The study’s in vivo analyses are limited to murine tumor models, and human tumor microenvironment complexity may affect translatability. The specificity of copper delivery and potential off-target effects warrant further investigation, especially given the known toxicity of copper overload. Additionally, the long-term effects of metabolic disruption on non-tumor tissues have not been fully characterized (paper).

Protocol Parameters

• assay | copper-tannic acid nanosystem (SCu/L) | 50–100 μg/mL | optimal for in vitro induction of ferroptosis/cuproptosis in cancer cells | paper
• assay | STF-31 (glycolysis/NAD+ inhibitor) | 5–10 μM (encapsulated) | effective for metabolic inhibition within nanosystem | paper
• assay | Deferoxamine (DeferoxamineB) | ≥6 mg/mL in water (with ultrasonic) | for iron chelation/ferroptosis inhibition controls in cell culture | product_spec
• assay | storage of Deferoxamine | -20°C | preserves compound stability for experimental workflows | product_spec
• assay | tumor model | murine (4T1) | preclinical evaluation of nanotherapeutic efficacy and immune response | paper
• assay | lipid peroxidation (ferroptosis readout) | C11-BODIPY staining | quantifies ferroptosis-specific cell death | paper
• assay | protein oligomerization (cuproptosis readout) | western blot for mitochondrial protein aggregates | confirms cuproptosis | paper
• assay | apoptosis/autophagy modulation by Deferoxamine | 10–100 μM | for comparative studies in cancer cell lines | workflow_recommendation

Research Support Resources

Researchers aiming to reproduce or extend metabolic intervention workflows in ferroptosis/cuproptosis studies can utilize Deferoxamine (DeferoxamineB) (SKU BA2746) as a validated iron chelator, apoptosis inducer, and autophagy inducer in cancer cell culture and biochemical assays. Supplied by APExBIO, DeferoxamineB offers robust solubility and storage parameters (optimum at -20°C), supporting its integration into regulated cell death and metabolic modulation research. For further assay design strategies and troubleshooting, consult internal guides such as "Deferoxamine: Applied Workflows for Iron Chelation in Cancer Research."